Drug news
FDA expands Zytiga (Janssen Biotech) indication in Prostate Cancer
The FDA has expanded the approved use of Zytiga (abiraterone acetate) from Janssen Biotech, to treat men with late-stage (metastatic) castration-resistant Prostate Cancer prior to receiving chemotherapy. The FDA initially approved Zytiga in April 2011 for use in patients whose Prostate Cancer progressed after treatment with docetaxel, a chemotherapy drug. Zytiga is a pill that decreases the production of male sex hormone testosterone.